This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Addgene
product type :
cDNA
product name :
TFORF2095
catalog :
141918
citations: 1
product information
Catalog Number :
141918
Product Name :
TFORF2095
article :
doi | 10.1016/j.cell.2022.11.026 |
id | 28211165 |
pubmed_id | 36608654 |
bacterial resistance :
Ampicillin
cloning :
backbone | pLX_TRC317 | ||
backbone_mutation | |||
backbone_origin | Broad Institute Genetic Perturbation Platform | ||
backbone_size | 8264 | ||
promoter | |||
sequencing_primer_3 | |||
sequencing_primer_5 | |||
vector_types |
|
growth notes :
NM_014682,XM_011517633,XM_017014063,XM_017014058,XM_011517632,XM_017014061,XM_017014071,XM_017014067,XM_017014054,XM_017014065,XM_017014053,XM_017014068,XM_017014048,XM_017014047,XM_017014051,XM_017014069,XM_017014064,XM_011517636,XM_017014062,XM_017014070,XM_011517635,XM_011517634,XM_017014066,XM_011517631,XM_011517629,XM_006716487,XM_011517637,XM_017014056,XM_017014052,XM_017014049,XM_017014057,XM_017014060,XM_017014059,XM_017014050,XM_017014055,XM_011517638,ENST00000276480 . The transcription factor ORF portion of this plasmid was synthesized by Genewiz. Please test multiple small colonies in case of plasmid recombination. To make this collection available in a timely manner, a portion of this collection was not fully sequenced by Addgene. If an Addgene verified full plasmid sequence is not available, please contact us at help@addgene.org prior to placing an order to request the full sequence.
growth strain :
Lentiviral vector for overexpressing transcription factor ORFs with unique 24-bp barcodes. Barcodes facilitate identification of transcription factors in pooled screens.
origin :
37
pi :
|
resistance markers :
898 |
tags :
High Copy
terms :
Puromycin |
company information
Addgene
490 Arsenal Way, Suite 100
Watertown, MA 02472
Watertown, MA 02472
info@addgene.org
https://www.addgene.org617.225.9000
headquarters: USA
questions and comments